M. Helen Huls

6.9k citations

48 papers · 4.9k indexed · 2 hit papers · h-index 27

Oncology top 0.5%
Immunology top 1%
Genetics top 1%
Epidemiology top 2%
Molecular Biology top 10%

Co-authors: Cliona M. Rooney Helen E. Heslop Malcolm K. Brenner Adrian P. Gee Catherine M. Bollard Heidi L. Weiss Gary D. Myers Karin Straathof
Topics: Viral-associated cancers and disorders (23 papers)Immune Cell Function and Interaction (19 papers)Cytomegalovirus and herpesvirus research (18 papers)
Cited by: Oncology Immunology Genetics
Journals: Proceedings of the National Academy of Sciences Nature Medicine The Journal of Experimental Medicine
Partner nations: United States France United Kingdom

In The Last Decade

M. Helen Huls

47 papers receiving 4.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

2008 919 citations Martin Pulé, Barbara Savoldo et al. Nature Medicine profile →
Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells

2012 489 citations Cecele J. Denman, V. V. Senyukov et al. PLoS ONE profile →

Peers

Countries citing papers authored by M. Helen Huls

Since Specialization

Citations

This map shows the geographic impact of M. Helen Huls's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Helen Huls with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Helen Huls more than expected).

Fields of papers citing papers by M. Helen Huls

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Helen Huls. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Helen Huls. The network helps show where M. Helen Huls may publish in the future.

Co-authorship network of co-authors of M. Helen Huls

This figure shows the co-authorship network connecting the top 25 collaborators of M. Helen Huls. A scholar is included among the top collaborators of M. Helen Huls based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Helen Huls. M. Helen Huls is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations 2015 ·PLoS ONE ·Drew C. Deniger,Jianqiang Yu,M. Helen Huls,Matthew J. Figliola,Tiejuan Mi,Sourindra N. Maiti,George F. Widhopf,Lenka V. Hurton,Radhika Thokala,Harjeet Singh,Simon Olivares,Richard E. Champlin,William G. Wierda,Thomas J. Kipps,Laurence J.N. Cooper	44
2	Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor 2015 ·Cancer Gene Therapy ·Harjeet Singh,Judy S. Moyes,M. Helen Huls,Laurence J.N. Cooper	63
3	Activating and Propagating Polyclonal Gamma Delta T Cells with Broad Specificity for Malignancies 2014 ·Clinical Cancer Research ·Drew C. Deniger,Sourindra N. Maiti,Tiejuan Mi,Kirsten C. Switzer,Vijaya Ramachandran,Lenka V. Hurton,Sonny Ang,Simon Olivares,Brian Rabinovich,M. Helen Huls,Dean A. Lee,Robert C. Bast,Richard E. Champlin,Laurence J.N. Cooper	104
4	Clinical Application of <em>Sleeping Beauty</em> and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood 2013 ·Journal of Visualized Experiments ·M. Helen Huls,Matthew J. Figliola,Margaret J. Dawson,Simon Olivares,Partow Kebriaei,Elizabeth J. Shpall,Richard E. Champlin,Harjeet Singh,Laurence J.N. Cooper	43
5	Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cellsbreakdown → 2012 ·PLoS ONE ·Cecele J. Denman,V. V. Senyukov,Srinivas S. Somanchi,Prasad V. Phatarpekar,Lisa M. Kopp,Jennifer L. Johnson,Harjeet Singh,Lenka V. Hurton,Sourindra N. Maiti,M. Helen Huls,Richard E. Champlin,Laurence J.N. Cooper,Dean A. Lee	489
6	Adoptive Transfer of EBV-specific T Cells Results in Sustained Clinical Responses in Patients With Locoregional Nasopharyngeal Carcinoma 2010 ·Journal of Immunotherapy ·Chrystal U. Louis,Karin Straathof,Catherine M. Bollard,(unknown),Claudia Gerken,Teresita Lopez,M. Helen Huls,Andrea M. Sheehan,Meng-Fen Wu,(unknown),Adrian P. Gee,Malcolm K. Brenner,Cliona M. Rooney,Helen E. Heslop,Stephen Gottschalk	160
7	Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastomabreakdown → 2008 ·Nature Medicine ·Martin Pulé,Barbara Savoldo,Gary D. Myers,Claudia Rössig,Heidi V. Russell,Gianpietro Dotti,M. Helen Huls,Enli Liu,Adrian P. Gee,Zhuyong Mei,Éric Yvon,Heidi L. Weiss,Hao Liu,Cliona M. Rooney,Helen E. Heslop,Malcolm K. Brenner	919
8	In vivoexpansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation 2006 ·Leukemia & lymphoma ·Catherine M. Bollard,Stephen Gottschalk,M. Helen Huls,Jeffrey J. Molldrem,Donna Przepiorka,Cliona M. Rooney,Helen E. Heslop	15
9	Administration of Latent Membrane Protein 2–Specific Cytotoxic T Lymphocytes to Patients with Relapsed Epstein-Barr Virus–Positive Lymphoma 2006 ·Clinical Lymphoma & Myeloma ·Catherine M. Bollard,M. Helen Huls,Elizabeth L. Buza,Heidi L. Weiss,Vicky Torrano,Mary V. Gresik,Jeff Chang,Adrian P. Gee,Stephen Gottschalk,George Carrum,Malcolm K. Brenner,Cliona M. Rooney,Helen E. Heslop	16
10	Slc11a1 (formerly Nramp1) polymorphisms and susceptibility to post‐transplant lymphoproliferative disease following pediatric liver transplantation 2006 ·Transplant Infectious Disease ·Neal R. Barshes,(unknown),John A. Goss,(unknown),M. Helen Huls,Cliona M. Rooney,Saul J. Karpen,Samuel Wyllie	3
11	Options for T‐cell based therapies 2004 ·Vox Sanguinis ·HE Heslop,Stephen Gottschalk,Catherine M. Bollard,Karin Straathof,M. Helen Huls,M.K. Brenner,Cliona M. Rooney	1
12	The Generation and Characterization of LMP2-Specific CTLs for Use as Adoptive Transfer From Patients With Relapsed EBV-Positive Hodgkin Disease 2004 ·Journal of Immunotherapy ·Catherine M. Bollard,Karin Straathof,M. Helen Huls,(unknown),(unknown),Alan R. Davis,Stephen Gottschalk,Malcolm K. Brenner,Helen E. Heslop,Cliona M. Rooney	83
13	A strategy for treatment of Epstein–Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells 2003 ·Cancer Gene Therapy ·Hans‐Joachim Wagner,Catherine M. Bollard,Stéphane Vigouroux,M. Helen Huls,Robert J. Anderson,H. G. Prentice,Malcolm K. Brenner,Helen E. Heslop,Cliona M. Rooney	63
14	Adoptive T-Cell Therapy for Epstein-Barr Virus-Positive Hodgkin’s Disease 2003 ·Acta Haematologica ·M. Helen Huls,Cliona M. Rooney,Helen E. Heslop	7
15	Large-Scale Expansion of Dendritic Cell-Primed Polyclonal Human Cytotoxic T-Lymphocyte Lines Using Lymphoblastoid Cell Lines for Adoptive Immunotherapy 2003 ·Journal of Immunotherapy ·Uluhan Sili,M. Helen Huls,Alan R. Davis,Stephen Gottschalk,Malcolm K. Brenner,Helen E. Heslop,Cliona M. Rooney	48
16	Generation of EBV-Specific CD4+ Cytotoxic T Cells from Virus Naive Individuals 2002 ·The Journal of Immunology ·Barbara Savoldo,(unknown),April Durett,John A. Goss,M. Helen Huls,Zhensheng Liu,Teresita Lopez,Adrian P. Gee,Paul D. Ling,Malcolm K. Brenner,Helen E. Heslop,Cliona M. Rooney	88
17	Immune therapy for EBV infections after hemopoietic stem-cell transplant 2002 ·Cytotherapy ·(unknown),Catherine M. Bollard,Stephen Gottschalk,Ingrid Kuehnle,M. Helen Huls,Adrian P. Gee,(unknown),Cliona M. Rooney	5
18	GENERATION OF AUTOLOGOUS EPSTEIN-BARR VIRUS???SPECIFIC CYTOTOXIC T CELLS FOR ADOPTIVE IMMUNOTHERAPY IN SOLID ORGAN TRANSPLANT RECIPIENTS1 2001 ·Transplantation ·Barbara Savoldo,John A. Goss,Zhensheng Liu,M. Helen Huls,(unknown),Adrian P. Gee,Malcolm K. Brenner,Helen E. Heslop,Cliona M. Rooney	65
19	Adoptive Immunotherapy of EBV-Associated Malignancies with EBV-Specific Cytotoxic T-Cell Lines 2001 ·Current topics in microbiology and immunology ·Cliona M. Rooney,Laura K. Aguilar,M. Helen Huls,Malcolm K. Brenner,HE Heslop	37
20	Dexamethasone effects on creatine kinase activity and insulin‐like growth factor receptors in cultured muscle cells 1989 ·Journal of Cellular Physiology ·Peggy A. Whitson,Charles Stuart,M. Helen Huls,Clarence F. Sams,Nitza M. Cintrón	23

About M. Helen Huls

M. Helen Huls is a scholar working on Oncology, Immunology and Epidemiology, having authored 48 papers that have together received 4.9k indexed citations. Recurring topics across this work include Viral-associated cancers and disorders (23 papers), Immune Cell Function and Interaction (19 papers) and Cytomegalovirus and herpesvirus research (18 papers). The work is most often cited by research in Oncology (3.9k citations), Immunology (2.4k citations) and Genetics (1.2k citations). M. Helen Huls has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include Cliona M. Rooney, Helen E. Heslop, Malcolm K. Brenner, Adrian P. Gee, Catherine M. Bollard, Heidi L. Weiss, Gary D. Myers, Karin Straathof, Claudia Rössig and Laurence J.N. Cooper. Their work appears in journals such as Proceedings of the National Academy of Sciences, Nature Medicine and The Journal of Experimental Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact